Allergen-specific sublingual immunotherapy for respiratory allergy

BioDrugs

Volumn 15, Issue 8, 2001, Pages 509-519

  Passalacqua, Giovanni ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BIOLOGICAL RESPONSE MODIFIER;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; DRUG DISPOSITION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG SURVEILLANCE PROGRAM; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOTHERAPY; MEDICAL SOCIETY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT ALLERGY; REVIEW;

EID: 0034786034     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115080-00003     Document Type: Review

References (87)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 1: 1572-3
2. Black JH. The oral administration of pollen: clinical report. J Lab Clin Med 1928; 13:709
3. Dunbar P. The present state of knowledge of hayfever. J Hyg 1913; 13: 105
4. Passalacqua G, Albano M, Riccio A, et al. Local nasal immunotherapy: experimental evidences and general considerations. Allergy 1997; 52 (33 Suppl.): 10-6
5. Herxeimer H. Bronchial hypersensitization and hyposensitization in man. Int Arch Allergy Appl Immunol 1951; 40:40-57
6. Committee on the safety of medicines. CSM update. Desensitizing vaccines. BMJ 1986; 293: 948
7. Lockey RF, Benedict LM, Turkeltaub PC, et al. Fatalities from immunotherapy and skin testing. J Allergy Clin Immunol 1987; 79: 660-77
8. Reid MJ, Lockey RF, Turkeltaub PC, et al. Survey of fatalities from skin testing and immunotherapy. J Allergy Clin Immunol 1993; 92: 6-15
9. Mailing HJ, Weeke B. Immunotherapy. Position paper of the European Academy of Allergology and Clinical Immunology. Allergy 1993; 48 Suppl. 14: 9-35
10. Bousquet J, Lockey R, Mailing HJ, editors. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization Position Paper. Allergy 1998: 53 Suppl. 44: 1-29
11. Mailing HJ, Abreu-Nogueira J, Alvarez-Cuesta E, et al. Local immunotherapy. Position paper of the EAACI/ESPACI working group. Allergy 1998: 53: 933-44
12. Passalacqua G, Bagnasco M, Mariani G, et al. Local immunotherapy: pharmacokinetics and efficacy. Allergy 1998; 53: Supl. 44: 477-84
13. Gleich GJ, Zimmermann EM. Henderson LL, et al. Effect of immunotherapy on immunoglobulins E and G to ragweed antigens. A six year prospective study. J Allergy Clin Immunol 1982; 70: 261-71
14. Furin MJ, Norman PS, Creticos PS, et al. Immunotherapy decreases antigen-induced eosinophil migration into the nasal cavity. J Allergy Clin Immunol 1989; 88: 27-32
15. Rak S, Hakanson L, Venge P. Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity. J Allergy Clin Immunol 1990; 86: 706-11
16. Secrist H, Dekruyff RH, Umetsu DT. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentrations and antigen presenting cell type. J Exp Med 1995; 181: 1081-9
17. Varney VA, Hamid QA, Gaga M. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during late phase cutaneous response. Clin Invest 1993; 92: 644-51
18. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med 1999; 341:468-75
19. Durham SR, Till SJ. Immunological changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998; 102: 157-65
20. Giannarini L. Maggi E. Decrease of allergen specific T cell response induced by nasal immunotherapy. Clin Exp Allergy 1998; 28: 404-12
21. Fanta C, Bohl B, Hirt W. et al. Systemic immunological changes induced by administration of grass pollen extract via oral mucosa during SLIT. Int Arch Allergy Immunol 1999; 120: 218-24
22. Tsitoure DC, DeKruyff RH, Lamb JR. et al. Intranasal exposure to antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J Immunol 1999; 163: 2592-600
23. Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic in-flammation in mite induced rhinoconjunctivitis. Lancet 1998; 351:629-32
24. Passalacqua G, Albano M, Riccio AM, et al. Clinical and immunologie effects of a rush sublingual immunotherapy to Parietaria species: a double blind placebo controlled trial. J Allergy Clin Immunol 1999; 104: 964-8
25. Passalacqua G, Albano M, Ruffoni S, et al. Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. Am J Respir Crit Care Med 1995 ; 152: 461 -6
26. Chen Y, Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237-40
27. Holt PG, Vines J, Britten D. Sublingual allergen administration. I. Selective suppression of IgE production in rats with high allergen doses. Clin Allergy 1988; 18: 229-34
28. Mowart AM. The regulation of immune response to dietary proteins. Immunol Today 1987; 8: 93-6
29. Miller A, Lider O, Roberts AB, et al. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune response by the release of TGF beta following antigen specific triggering. Proc Natl Acad Sci USA 1992; 89: 421-5
30. Hasseus B, Dahlgren U, Bergenholtz G, et al. Antigen presenting capacity of Langerhans cells from rat oral epithelium. J Oral Pathol Med 1995; 24: 56-60
31. VanWilsem EJ, Van Hoogsraten IM, Breve J, et al. Dendritic cells of the oral mucosa and the induction of oral tolerance. A local affair. Immunology 1994; 93: 128-32
32. Macatinia SE, Hosken NA. Dendritic cells produce IL-12 and direct the development of TH1 cells from naive CD4+ T cells. J Immunol 1995; 154:5071-9
33. Holt PG, McMenamin C. Defense against allergic sensitization in healthy lung: the role of inhalation tolerance. Clin Exp Allergy 1989; 19: 55-62
34. Holt PG. Sedgwick JD. Suppression of IgE response following antigen inhalation: anatural homeostatic mechanism which limits sensitizations to aeroallergens. Immunol Today 1987; 8: 14-5
35. Einarsson R, Renck B, Taudorf E. In vitro studies of degradation of birch and timothy pollen allergen preparations by human duodenal juice. Allergy 1988; 43: 469-75
36. Falagiani P, Mistrello G. Pharmacokinetics of allergens after local administration. Allergy 1997; 52 (33): 17-21
37. Mistrello G, Rapisarda G, Falagiani P. Detection of IgE-binding activity in serum after intranasal treatment of normal rabbits with P. judaica extracts. Allergy 1991 ; 46: 52-5
38. Mistrello G, Roncarolo D, Gentili M, et al. Modified par j I allergen from P. judaica pollen and its rate of absorption in rats. Immunol Lett 1993; 40: 31-6
39. Swarbrick ET, Stokes CR, Soothill JF. Absorption of antigens after oral immunisation and the simultaneous induction of specific tolerance. Gut 1979; 20: 121-3
40. Buckle FB, Cohen AB. Nasal mucosal hyperpermeability to macromolecules in atopic rhinitis and extrinsic asthma. J Allergy Clin Immunol 1975; 55: 213-21
41. Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol 1997; 100: 121-9
42. Bagnasco M, Passalacqua G, Villa G, et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001; 31:54-60
43. Casanovas M, Guerra F, Moreno C, et al. Double-blind placebocontrolled clinical trial of preseasonal treatment with allergenic extracts of Otea europaea pollen administered sublingually. 1 Invest Allergol Clin Immunol 1994; 4: 305-14
44. Feliziani V, Marfïsi RM, Parmiani S. Rush immunotherapy with sublingual administration of grass allergen extract. Allergol Imrmmopathol 1993; 21: 173-8
45. Nelson HS, Oppenheimer J, Vatsia GA, et al. A double blind placebo controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993; 92: 229-36
46. Novembre E, Marano E, Bernardini R, et al. Studio controllato suH'immunoterapia sublinguale nel trattamento dell'asma allergico nel bambino. Riv It Fed 1991; 17: 75-8
47. Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986; 16: 483-91
48. Van Niekerk CH, De Wet JI. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay fever: a double blind study. Clin Allergy 1987; 17: 507-13
49. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. Adouble blind study. Allergol Immunopathol 1990; 18:277-84
50. Sabbah A, Hassoun S, Le Sellin J, et al. A double blind placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994; 49: 309-13
51. Troise C, Voltolini S, Canessa A, et al. Sublingual immunotherapy in Parietaria pollen induced rhinitis: a double blind study. J Invest Allergol Clin Immunol 1995; 5: 25-30
52. Feliziani V, Lattuada G, Parmiani S, et al. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol 1995; 23: 173-8
53. Hirsch T, Sahn M, Leupold W. Double blind placebo controlled study of sublingual immunotherapy with house dust mite extracts in children. Pediatr Allergy Immunol 1997; 8: 21-7
54. Clavel R, Bousquet J, André C. Clinical efficacy of sublingual swallow immunotherapy: a double blind placebo controlled trial of a standardized five grass pollen extract in rhinitis. Allergy 1998:53:493-8
55. Horak F, Stubner UE, Berger U, et al. Immunotherapy with sublingual birch pollen extract: a short term double blind study. J Invest Allergol Clin Immunol 1998; 8: 165-71
56. Vourdas D, Syrigou E, Potamianou P, et al. Double blind placebo controlled evaluation of sublingual immunotherapy with a standardized olive tree pollen extract in pédiatrie patients with allergie rhinoconjunctivitis and mild asthma due to olive tree pollen sensitization. Allergy 1998; 53: 662-71
57. Bousquet J, Scheinmann P, Guinnepain MT, et al. Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: a double blind placebo controlled study. Allergy 1999:54:249-60
58. Hordijk GJ, Antwelink JB, Luwema RA. Sublingual immunotherapy with a standardized grass pollen extract: a double blind placebo controlled study. Allergol Immunopathol 1998: 26: 234-40
59. Purello D'Ambrosio F, Gangemi S, Isola S, et al. Sublingual immunotherapy: a double blind placebo controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma or both. Allergy 1999:54:968-73
60. Pradalier A, Basset D, Claudel A, et al. Sublingual swallow immunotherapy (SLIT) with a standardized five grass pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999; 54: 819-28
61. La Rosa M, Ranno C, André C, et al. Double blind placebo controlled evaluation of sublingual swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104:425-32
62. Guez S, Vatrinet C, Fadel R, et al. House dust mite sublingual swallow immunotherapy in perennial rhinitis: a double blind placebo controlled study. Allergy 2000; 55: 369-75
63. Pajno GB, Morabito L, Barberio G. et al. Clinical and immunological effects of longterm sublingual immunotherapy in asthmatic children sensitized to mite: a double blind study. Allergy 2000: 55: 842-9
64. Caffarelli C, Sensi LG, Marcucci F, et al. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000; 55: 1142-7
65. Lombardi C, Gargioni S, Venturi S, et al. Controlled study of preseasonal immunotherapy with grass pollen extract in tablets: effect on bronchial hyperreactivity. J Invest Allergol Clin Immunol 2001; 11:41-5
66. Quirino T, lemoli E, Siciliani E, et al. Sublingual vs injective immunotherapy in grass pollen allergic patients: a double blind double dummy study. Clin Exp Allergy 1996; 26: 1253-61
67. Bernardis P. Agnoletto M, Puccinelli P, et al. Injective vs sublingual immunotherapy in Alternaria tenuis allergic patients. J Invest Allergol Clin Immunol 1996; 6: 55-62
68. Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma: a placebo controlled study. Ann Allergy Asthma Immunol 1999; 82: 485-90
69. Khinchi S, Poulsen LK, Carat F, et al. Clinical efficacy of sublingual swallow and subcutaneous immunotherapy in patients with allergic rhinoconjunctivitis due to birch pollen. A double blind double dummy placebo controlled study [abstract]. Allergy 55 Suppl. 63: 24
70. Almangro E, Assensio O, Bartolome JM, et al. Estudio multicentrico de farmacovigilancia de imunoterapia sublingual en pacientes alergicos. Allergol Immunopathol 1995; 23: 153
71. Di Rienzo V, Pagani A, Parmiani S, et al. Post-marketing surveillance study on the safety of sublingual immunotherapy in children Allergy 1999; 54: 1110-3
72. Lombardi C, Canonica GW, Passalacqua G. Sublingual immunotherapy is clinically safe in patients with oral allergy syndrome. Allergy 2000; 55: 677-8
73. André C, Vatrinet C. Galvain S, et al. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121:229-34
74. Frew AJ, White PJ. Sublingual immunotherapy. J Allergy Clin Immunol 1999; 104: 267-70
75. Allergic rhinitis and its impact on asthma (ARIA). Workshop report. WHO Position Paper. Bousquet J, Kalthaev N, Van Cauwenberge P. Chairs. Presented at the XXth European Academy of Allergology and Clinical Immunology (EAACI) Congress; 2001 May 9-13; Berlin
76. Van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55: 116-34
77. Passalacqua G, Canonica GW. Alternative routes for allergen specific immunotherapy. J Invest Allergol Clin Immunol 1996; 6: 81-7
78. The use of standardized allergen extracts. Position Statement. American Academy of Allergy, Asthma and Immunology (AAAAI). J Allergy Clin Immunol 1997; 99: 583-6
79. Lower T, Hensy J, Mandik L, et al. Compliance with allergen immunotherapy. Ann Allergy 1993; 70: 480-2
80. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993; 91: 734-7
81. Jacobsen L. PAT Preventive Allergy Treatment. Symposium on Specific Allergy. Clin Exp Allergy 1996; 26: 80-5
82. Des Roches A, Paradis L, Mènardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitisations in children. J Allergy Clin Immunol 1997; 99: 450-3
83. Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995; 96: 879-85
84. Ariano R, Augeri G, Kroon AM, et al. Longterm treatment with allergoid immunotherapy with Parietaria. Clinic and immunological effects in a randomized controlled trial. Allergy 1999; 54: 313-9
85. Frew AJ, Smith PJ. Sublingual immunotherapy. J Allergy Clin Immunol 2001; 107: 441-4
86. Simons FER. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1994; 104: 534-40
87. Passalacqua G, Ciprandi G, Canonica GW. The nose-lung interaction in allergic rhinitis and asthma: the united airways disease. Curr Opin Allergy Clin Immunol 2001; 1: 7-14 Correspondence and offprints: Dr Giorgio Walter Canonica, Allergy & Respiratory Diseases, DIMI, Padiglione Maragliano, L.go R. Benzi 10,16132 Genoa, Italy. gcanonica@qubisoft.it